Association of Tumor Mutational Burden and Microsatellite Instability With Response and Outcomes in Patients With Urothelial Carcinoma Treated With Immune Checkpoint Inhibitor.

doi:10.1016/j.clgc.2024.102198

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Association of Tumor Mutational Burden and Microsatellite Instability With Response and Outcomes in Patients With Urothelial Carcinoma Treated With Immune Checkpoint Inhibitor.

Clinical genitourinary cancer - 1 Dec 2024

Bakaloudi Dimitra Rafailia, Talukder Rafee, Makrakis Dimitrios, Diamantopoulos Leonidas, Enright Thomas, Leary Jacob B, Patgunarajah Ubenthira, Thomas Vinay M, Swami Umang, Agarwal Neeraj, Jindal Tanya, Koshkin Vadim S, Brown Jason R, Barata Pedro, Murgić Jure, Miletić Marija, Johnson Jeffrey, Zakharia Yousef, Hui Gavin, Drakaki Alexandra, Duran Ignacio, Buznego Lucia A, Barrera Rafael M, Castañeda David M, Rey-Cárdenas Macarena, Castellano Daniel, Nguyen Charles B, Park Joseph J, Alva Ajjai, McKay Rana R, Stewart Tyler F, Epstein Ilana B, Bellmunt Joaquim, Wright Jonathan L, Gupta Shilpa, Grivas Petros, Khaki Ali Raza

Abstract excerpt

BACKGROUND: Microsatellite Instability (MSI) and Tumor Mutational Burden (TMB) are associated with immune checkpoint inhibitor (ICI) efficacy. We examined the association between TMB and MSI status with survival in patients with urothelial carcinoma (UC) treated with ICI. METHODS: Patients from 15 institutions were treated with ICI monotherapy. Primary endpoint was overall survival and secondary endpoints...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibodies, Monoclonal, Humanized

Share to Biomarkers, Tumor

Share to Carcinoma, Transitional Cell

Share to Immune Checkpoint Inhibitors

Share to Microsatellite Instability

Share to Progression-Free Survival

Share to Treatment Outcome

Share to Urologic Neoplasms

Source

Open in PubMed

Identifiers

PMID: 39241315
DOI: 10.1016/j.clgc.2024.102198

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Association of Tumor Mutational Burden and Microsatellite Instability With Response and Outcomes in Patients With Urothelial Carcinoma Treated With Immune Checkpoint Inhibitor.PMID 39241315Read ↗

Tumor Mutational Burden Predicting the Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

Frequency of microsatellite instability (MSI) in upper tract urothelial carcinoma: comparison of the Bethesda panel and the Idylla MSI assay in a consecutively collected, multi-institutional cohortSemantic proximity Read ↗

Tumor Mutational Burden, Toxicity, and Response of Immune Checkpoint Inhibitors Targeting PD(L)1, CTLA-4, and Combination: A Meta-regression Analysis.Semantic proximity Read ↗

MDM2/4 amplification predicts poor response to immune checkpoint inhibitors: a pan-cancer analysisSemantic proximity Read ↗

Alterations of DNA damage response genes correlate with response and overall survival in anti-PD-1/PD-L1-treated advanced urothelial cancer.Semantic proximity Read ↗

Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes.Semantic proximity Read ↗

Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma.Semantic proximity Read ↗

Nivolumab in Patients with Advanced Platinum-resistant Urothelial Carcinoma: Efficacy, Safety, and Biomarker Analyses with Extended Follow-up from CheckMate 275.Semantic proximity Read ↗

Performance of Low-Dose Immunotherapy and Standard-Dose Immunotherapy in Microsatellite Instability-High Metastatic Colorectal Cancer: Real-World Data (CLouD—High Study)Semantic proximity Read ↗

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.